11
Consolidation
durvalumab
for up to 12
months
Sequential
chemotherapy
and RT
RT alone
Patients
who are not
candidates for
chemotherapy
Patients who are
not candidates
for concurrent
chemoradiotherapy
but are candidates
for chemotherapy
Concurrent
chemotherapy
and RT
Patients with
good PS
Patients who
are medically
or surgically
inoperable
Unresectable
No disease
progression
Patients receiving
definitive
radiation
in standard
fractionation may
be considered
for radiation
dose escalation
and for modest
hypofractionation
form 2.14–4 Gy
per fraction
Arrows with dotted lines indicate the level of obligation is a "May" (Moderate) recommendation.
1
Patients with stage III NSCLC generally should not be excluded from consideration for surgery
by nonsurgical physicians.
2
Carboplatin may be substituted for cisplatin in patients with contraindications to or deemed
ineligible for cisplatin.
